CNS Clinical Trials 2010 Will Address Drug Development Issues in One of the Fastest Growing Therapeutic Areas
Global patient recruitment thought leader Liz Moench of MediciGlobal and Stephan Mittermeyer of BrainLAB will chair and present at the 2-day industry conference in London, UK
King of Prussia, PA and London, UK (August 23, 2010) – CNS is one of the largest and fastest growing therapeutic areas of the pharmaceutical market and conducting clinical trials in CNS poses unique challenges and considerations. An upcoming conference in September is dedicated to drug development in this important therapeutic area.
Presentations and discussions will focus on new and emerging treatments in CNS for conditions including epilepsy, depression, bipolar disorder and neurodegenerative disorders affecting the ageing baby-boom generation including multiple sclerosis, Alzheimer’s disease and Parkinson’s disease. Increasing disease prevalence and a robust pipeline make this sector dynamic and highly promising for biopharmaceutical companies worldwide.
This year’s CNS Clinical Trials 2010 will be held September 16th - 17th, 2010 in London UK, and will focus on strategies for success and overcoming challenges faced in CNS drug development. As part of this 2-day event, leading industry and academic authorities will address how to balance risk, how attrition can be reduced and how to optimise success in CNS clinical trials; overcoming hurdles in designing, managing and recruiting for CNS clinical trials, and consideration of tools and technologies to enhance clinical development.
Liz Moench, president and CEO of global patient recruitment organisation MediciGlobal, will chair day one of the conference, and deliver a presentation focussed on recruiting CNS patients in a changing recruitment environment. Stephan Mittermeyer of BrainLAB will chair day two. This industry leadership conference, CNS Clinical Trials 2010, will be held at Thistle Marble Arch, Bryanston Street, London.
Organized by Visiongain Inc, considerable planning has culminated into an extensive programme that spans issues related to assessing cognitive function, neuroimaging, patient recruitment and retention, statistical thinking for designing adaptive trials, regulatory challenges, biomarkers for Proof of Concept in CNS clinical trials, patients communications, ethical consent and more.
Importantly, conference registrants will have the opportunity to network with a range of industry leaders. Be part of a major networking opportunity.
Conference organizers:
Conference venue: Thistle Hotel- Marble Arch, T: 0871 376 9027 / +44 845 305 8327
http://www.thistle.com/hotels/united_kingdom/london/thistle_marble_arch/index.html
Conference programme: http://www.visiongain.com/Conference/257/CNS-Clinical-Trials
For support with patient recruitment for CNS clinical trials: http://www.MediciGlobal.com
###
About MediciGlobal
MediciGlobal is in the business of making a meaningful difference to patient health—by identifying and engaging patients for clinical trials, and by building deep and lasting connections with our many stakeholders. Our clinical trial recruitment practices are guided by global standards and by our concern for the lives of the patients who put their trust in us. We’re also making certain that those who participate in these trials fully understand what clinical trial participation means, and that their participation is guarded by strict privacy policies. MediciGlobal meets BBB OnLine® and WBENC accreditation standards and is certified as a Safe Harbor company. Visit www.mediciglobal.com and follow the company on Facebook at www.facebook.com/MediciGlobal.
www.mediciglobal.com
For further information contact:
Alicia Carango
+1 484-674-6855
acarango@MediciGlobal.com
